[시장보고서]세계의 파상풍 톡소이드 백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

세계의 파상풍 톡소이드 백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Tetanus Toxoid Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

상품코드 : 1820652

리서치사 : Value Market Research

발행일 : 2025년 07월

페이지 정보 : 영문 136 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,920

￦ 5,614,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730

￦ 6,774,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430

￦ 10,641,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 파상풍 톡소이드 백신 시장 예측은 상당한 성장을 예측하고 있습니다. 시장 규모는 2033년까지 100억 9,000만 달러로 급증할 전망이며, 2024년 59억 2,000만 달러에서 대폭 증가할 것으로 예측되고 있습니다. 이 확장은 2025-2033년 예상되는 6.11%라는 놀라운 CAGR을 반영합니다.

세계의 파상풍 톡소이드 백신 시장은 진행 중인 예방 접종 프로그램과 임산부 및 신생아 파상풍 박멸 이니셔티브에 견인되어 꾸준한 성장이 전망되고 있습니다. 혼합 백신이나 주사 바늘을 사용하지 않는 기술과 같은 백신 제형 및 전달의 발전으로 접종률 및 컴플라이언스가 향상되었습니다. 향후 개발은 내열성 백신 및 디지털 예방 접종 추적 시스템과의 통합을 주목할 것입니다.

게다가 개발도상국에서의 헬스케어 인프라와 의식의 향상으로 백신 접종의 범위가 확대되고 있습니다. WHO와 GAVI와 같은 조직의 세계 파트너십과 자금 지원은 대규모 예방 접종 캠페인을 지원합니다. 규제의 조화와 품질 관리는 백신의 안전성 및 효능을 향상시킵니다. 공중 보건 우선순위가 진화함에 따라 파상풍 톡소이드 백신 시장은 혁신을 지속하고 활용하기 쉽고 효과적이고 지속 가능한 예방 접종 솔루션을 제공할 것입니다.

개요 : 백신 유형별
과거 및 예측 데이터 분석 : 백신 유형별
파상풍 톡소이드(Tt)
디프테리아 및 파상풍(Dt)
파상풍 및 디프테리아(Td)
디프테리아, 파상풍, 백일해(Dtap)
파상풍, 디프테리아, 백일해(Tdap)
디프테리아, 파상풍, 백일해, 히브 및 B형 간염(Dtp-Hib-Hepb)
5가(Dtap-Ipv/Hib)
6가(Dtap-Ipv/Hib-Hepb)
기타 백신

제6장 세계의 파상풍 톡소이드 백신 시장 분석 : 연령층별

개요 : 연령층별
과거 및 예측 데이터 분석 : 연령층별
소아
성인

제7장 세계의 파상풍 톡소이드 백신 시장 분석 : 최종 용도별

개요 : 최종 용도별
과거 및 예측 데이터 분석 : 최종 용도별
병원 및 진료소
정부기관
기타 최종 사용자

제8장 세계의 파상풍 톡소이드 백신 시장 분석 : 지역별

지역별 전망
서문
북미의 매출 분석
- 개요, 분석 및 예측
- 북미 : 부문별
- 북미 국가별
- 미국
- 캐나다
- 멕시코
유럽의 매출 분석
- 개요, 분석 및 예측
- 유럽 : 부문별
- 유럽 국가별
- 영국
- 프랑스
- 독일
- 이탈리아
- 러시아
- 기타 유럽
아시아태평양의 매출 분석
- 개요, 분석 및 예측
- 아시아태평양 : 부문별
- 아시아태평양 국가별
- 중국
- 인도
- 일본
- 한국
- 호주
- 동남아시아
- 기타 아시아태평양
라틴아메리카의 매출 분석
- 개요, 분석 및 예측
- 라틴아메리카 : 부문별
- 라틴아메리카 국가별
- 브라질
- 아르헨티나
- 페루
- 칠레
- 기타 라틴아메리카
중동 및 아프리카의 매출 분석
- 개요, 분석 및 예측
- 중동 및 아프리카 : 부문별
- 중동 및 아프리카 국가별 일람
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카

제9장 파상풍 톡소이드 백신 기업 경쟁 구도

파상풍 톡소이드 백신 시장 경쟁
파트너십, 제휴 및 합의
합병 및 인수
신제품 발매
기타 개발

제10장 기업 프로파일

주요 기업의 시장 점유율 분석
시장 집중도
Bharat Biotech International Limited
Biological E. Limited
Biological Products Institute(BPI)Argentina
Chengdu Institute Of Biological Products Co. Ltd.
GlaxoSmithKline
Johnson & Johnson
Merck & Co. Inc.
Mitsubishi Tanabe Pharma Corporation
Panacea Biotec
Pfizer Inc.
Sanofi
Serum Institute Of India
Zydus Group

AJY

영문 목차

영문목차

The forecast for the global Tetanus Toxoid Vaccine market predicts substantial growth, with market size projected to soar to USD 10.09 Billion by 2033, a significant increase from the USD 5.92 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 6.11% anticipated between 2025 and 2033.

The global tetanus toxoid vaccine market is set for steady growth driven by ongoing immunization programs and maternal and neonatal tetanus elimination initiatives. Advances in vaccine formulation and delivery, including combination vaccines and needle-free technologies, are improving coverage and compliance. Future developments will focus on thermostable vaccines and integration with digital immunization tracking systems.

Moreover, increasing healthcare infrastructure and awareness in developing countries are expanding vaccination reach. Global partnerships and funding from organizations like WHO and GAVI are supporting mass immunization campaigns. Regulatory harmonization and quality control are enhancing vaccine safety and efficacy. As public health priorities evolve, the tetanus toxoid vaccine market will continue to innovate, delivering accessible, effective, and sustainable immunization solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Tetanus Toxoid Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vaccine Type

Tetanus Toxoid (Tt)
Diphtheria And Tetanus (Dt)
Tetanus And Diphtheria (Td)
Diphtheria, Tetanus, And Pertussis (Dtap)
Tetanus, Diphtheria, And Pertussis (Tdap)
Diphtheria, Tetanus, Pertussis, Hib And Hepatitis B (Dtp-Hib-Hepb)
Pentavalent (Dtap-Ipv/Hib)
Hexavalent (Dtap-Ipv/Hib-Hepb)
Other Vaccine Types

By Age Group

Pediatric
Adult

By End-Use

Hospitals And Clinics
Government Organizations
Other End-Users
List of Companies Profiled in the report
Bharat Biotech International Limited, Biological E. Limited, Biological Products Institute (BPI) Argentina, Chengdu Institute of Biological Products Co. Ltd., GlaxoSmithKline, Johnson & Johnson, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec, Pfizer Inc., Sanofi, Serum Institute of India, Zydus Group.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. TETANUS TOXOID VACCINE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Vaccine Type
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By End-Use
- 3.7.4 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL TETANUS TOXOID VACCINE MARKET ANALYSIS BY VACCINE TYPE

5.1. Overview By Vaccine Type
5.2. Historical and Forecast Data Analysis By Vaccine Type
5.3. Tetanus Toxoid (Tt) Historic and Forecast Sales By Regions
5.4. Diphtheria And Tetanus (Dt) Historic and Forecast Sales By Regions
5.5. Tetanus And Diphtheria (Td) Historic and Forecast Sales By Regions
5.6. Diphtheria, Tetanus, And Pertussis (Dtap) Historic and Forecast Sales By Regions
5.7. Tetanus, Diphtheria, And Pertussis (Tdap) Historic and Forecast Sales By Regions
5.8. Diphtheria, Tetanus, Pertussis, Hib And Hepatitis B (Dtp-Hib-Hepb) Historic and Forecast Sales By Regions
5.9. Pentavalent (Dtap-Ipv/Hib) Historic and Forecast Sales By Regions
5.10. Hexavalent (Dtap-Ipv/Hib-Hepb) Historic and Forecast Sales By Regions
5.11. Other Vaccine Types Historic and Forecast Sales By Regions

6. GLOBAL TETANUS TOXOID VACCINE MARKET ANALYSIS BY AGE GROUP

6.1. Overview By Age Group
6.2. Historical and Forecast Data Analysis By Age Group
6.3. Pediatric Historic and Forecast Sales By Regions
6.4. Adult Historic and Forecast Sales By Regions

7. GLOBAL TETANUS TOXOID VACCINE MARKET ANALYSIS BY END-USE

7.1. Overview By End-Use
7.2. Historical and Forecast Data Analysis By End-Use
7.3. Hospitals And Clinics Historic and Forecast Sales By Regions
7.4. Government Organizations Historic and Forecast Sales By Regions
7.5. Other End-Users Historic and Forecast Sales By Regions

8. GLOBAL TETANUS TOXOID VACCINE MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE TETANUS TOXOID VACCINE COMPANIES

9.1. Tetanus Toxoid Vaccine Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF TETANUS TOXOID VACCINE INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Bharat Biotech International Limited
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Biological E. Limited
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Biological Products Institute (BPI) Argentina
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Chengdu Institute Of Biological Products Co. Ltd.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. GlaxoSmithKline
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Johnson & Johnson
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Merck & Co. Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Mitsubishi Tanabe Pharma Corporation
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Panacea Biotec
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Pfizer Inc.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Sanofi
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Serum Institute Of India
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Zydus Group
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies